Resource Centre

Breathing new life into Phase 1 trials. Quotient's approach is helping Pulmatrix to develop a range of inhaled dry powder chemical entities based on its iSPERSE™ technology to meet unmet medical needs in multiple respiratory diseases.

An accelerated approach to clinical trials. Corcept Therapeutics is developing CORT125134, a promising candidate for the treatment of Cushing’s syndrome, a rare disorder associated with significant morbidity and mortality.

Clovis Oncology has chosen Quotient Sciences’ drug product optimization approach for rociletinib, a promising oral candidate drug for the treatment of EGFR-resistant non-small cell lung cancer.

Protein kinase inhibitors (PKIs) are used in the treatment of cancer and inflammation, but food interactions are a common problem with this class of drugs. Swedish drug delivery company Xspray has used its Hybrid Nanoparticle (HyNap™) technology to improve the bioavailability of the PKI nilotinib, reducing the required dose and significantly lowering the food interaction of the drug compared with the marketed product.

This white paper describes the benefits of our approach to poorly soluble drugs in terms of drug product performance and clinical decision-making, including case studies that demonstrate significant time and cost savings.

MK-X had demonstrated poor colonic absorption in dogs and conventional matrix based controlled release formulations failed to achieve adequate trough concentrations in a human pharmacokinetic (PK) study to support once daily dosing.